Botensilimab and balstilimab in metastatic, pre-treated MSS-CRC
Benjamin Schlechter, MD, Dana-Farber Cancer Institute, Boston, MA, presents expanded data from the microsatellite stable colorectal (MSS-CRC) expansion cohort of the Phase I study of botensilimab (NCT03860272), a multifunctional Fc-enhanced anti-CTLA-4, in combination with balstilimab, an anti-PD1 antibody, in metastatic heavily pre-treated MSS CRC. Efficacy was especially higher in patients without liver metastases, which form a significant minority of patients with MSS-CRC. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.